Athersys IncNASDAQ:ATHXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.7500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.7500/ 8
- Ask / Lots1.7700/ 2
- Open / Previous Close0.0000 / 1.7500
- Day Range---
- 52 Week Range
- Volume14,786
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | ATHX |
|---|
Feb 2, 2023
Athersys to Host Business Update Conference Call on February 14th, from 8:30AM ET on Thursday Feb 02, 2023 by Business Wire
8:30AM ET on Thursday Feb 02, 2023 by Business Wire
Jan 30, 2023
Athersys to Participate in International Stroke Conference and BioProcess International, from 11:20AM ET on Monday Jan 30, 2023 by Business Wire
11:20AM ET on Monday Jan 30, 2023 by Business Wire
Jan 25, 2023
BRIEF-Athersys Inc Has Until April 12 To Regain Nasdaq Compliance Under Market Value Standard, from 6:20PM ET on Wednesday Jan 25, 2023 by Thomson Reuters
6:20PM ET on Wednesday Jan 25, 2023 by Thomson Reuters
Jan 11, 2023
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January, from 12:11PM ET on Wednesday Jan 11, 2023 by Business Wire
12:11PM ET on Wednesday Jan 11, 2023 by Business Wire
Jan 9, 2023
BRIEF-Athersys Provides Multistem Clinical Update, from 8:58AM ET on Monday Jan 09, 2023 by Thomson Reuters
8:58AM ET on Monday Jan 09, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Athersys Inc | 22.6M | -0.2x | --- |
Aeterna Zentaris Inc | 18.6M | -1.8x | --- |
Pulmatrix Inc | 14.1M | -0.6x | --- |
Humanigen Inc | 27.1M | -0.2x | --- |
Inhibikase Therapeutics Inc | 19.2M | -1.0x | --- |
Cyclerion Therapeutics Inc | 29.8M | -0.6x | --- |
Company Information
Athersys, Inc. is a biotechnology company. It is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. It is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.
Contact Information
- Headquarters
- 3201 Carnegie AveCLEVELAND, OH, United States 44115-2634
- Phone
- 216-431-9900
- Fax
- 216-361-9495
Executives
- Independent Chairman of the Board
- Ismail Kola
- Chief Executive Officer, Director
- Daniel Camardo
- Interim Chief Financial Officer
- Kasey Rosado
- Chief Operating Officer
- Maia Hansen
- Director
- Joseph Nolan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.6M |
|---|---|
Revenue (TTM) | $6.0M |
Shares Outstanding | 12.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.72 |
EPS | $-8.00 |
Book Value | $1.69 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 3.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,413.53% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
